コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
2 ide conjugate vaccine, and then sequentially coinfected 5 weeks later with PR8 influenza virus and A6
3 ted a cross-sectional study among 50 HIV/HCV-coinfected, 51 HCV-monoinfected, and 50 HIV-monoinfected
4 in initiators vs nonusers among 7686 HIV/HCV-coinfected, 8155 HCV-monoinfected, 17739 HIV-monoinfecte
6 d that more than one distinct TSE strain can coinfect a single animal in natural field situations.
7 lls, the T6SS can also target other bacteria coinfecting a mammalian host, highlighting the importanc
8 observational cohort study included HIV/HCV-coinfected adults with genotype 1 HCV who initiated trea
13 The reduced number of lung effector cells in coinfected animals was associated with increased death,
16 y to influenza skews immune responses toward coinfecting bacteria and discover novel modes to prevent
18 icular stomatitis virus (VSV) as a model, we coinfected BHK cells with VSV DIPs and recombinant helpe
21 including human immunodeficiency virus (HIV)-coinfected cases) and rifampicin-resistant tuberculosis.
22 at this process is highly efficient within a coinfected cell and, given synchronous coinfection at mo
23 indirect cell-cell interactions prevent most coinfected cells from being completely suppressed by DIP
24 ent, and exchange of genetic segments inside coinfected cells occurs frequently within types but neve
25 porter expression acquired from thousands of coinfected cells reveal how interference acts at multipl
26 ssembly of heterologous gene segments within coinfected cells, and the fitness associated with reasso
27 These expansions were enhanced in CMV-EBV-coinfected children and were independent of varicella-zo
28 ration of critical drug-drug interactions in coinfected children, as these may significantly impact d
29 A-DR7-restricted CD4(+) T cells from the HIV-coinfected cohort that were specific for epitopes of HCM
30 estimates of recurrence in the high-risk and coinfected cohorts were driven by an increase in reinfec
33 cific CD4(+) T cells had been activated with coinfected DCs compared to Mtb-infected DCs, and this ef
38 enomic variation, we tracked reassortment in coinfected guinea pigs over time and given matched or di
40 is greatly inhibited by MRN and dependent on coinfecting helper virus, such as adenovirus, to remove
41 o characterize circulating CD4(+) T cells in coinfected HLA-DR7(+) long-term nonprogressor HIV subjec
42 une responses warrant further studies in HIV coinfected humans able to control their TB infection.
44 among human immunodeficiency virus (HIV)/HCV-coinfected individuals according to their baseline fibro
45 erates the progression of HCV disease; thus, coinfected individuals are at high priority for HCV trea
46 ency virus (HIV) and hepatitis C virus (HCV)-coinfected individuals have declined over the last decad
47 eased transition from latent to active TB in coinfected individuals have not been well elucidated at
48 reported at monthly visits in 3381 HIV/HSV-2-coinfected individuals in a placebo-controlled trial of
50 ited generalizability, since the majority of coinfected individuals were not eligible to participate.
52 d host factors that fuel disease severity in coinfected individuals will help guide the design of eff
53 0% for those with HCV infection, 29.5% among coinfected individuals, and 16.1% for those with neither
63 e treated 6 human immunodeficiency virus/HCV coinfected kidney transplant recipients with ledipasvir-
64 In contrast, independent of transplant era, coinfected LT recipients had increased risk for death (a
65 year, the limited options for treating those coinfected LT recipients with progressive recurrent HCV
67 pulmonary CD4(+) T cells was observed in all coinfected macaques, a subpopulation of the animals was
71 ents (94%) were human immunodeficiency virus coinfected (median CD4 count 16 cells/microL [interquart
73 ific CD8 T cells adoptively transferred into coinfected mice recapitulated the spectrum of helminth-i
78 increase pathogenicity, which was tested by coinfecting mice with L. guyanensis and lymphocytic chor
79 IV disrupts the balance between the host and coinfecting microbes, worsening control of these potenti
80 by ICD-9 codes were used to identify HIV/HBV coinfected (n = 144) and HBV monoinfected (n = 225) pati
82 sks (RRs) for an unfavorable response in the coinfected, non-HAART and HAART groups were 2.1 (95% con
84 try for Bcc and P. aeruginosa bacteria on 21 coinfected or singly infected CF lungs obtained at trans
89 autotaxin levels in HCV-infected and HCV-HIV-coinfected participants, compared with uninfected partic
90 rticipants and with Mac2BP levels in HCV-HIV-coinfected participants, while in HIV-infected individua
91 e hundred and thirty-three patients (56% HIV coinfected) participated, and 15 unfavorable outcomes we
92 s on within-host biology, the role played by coinfecting pathogens on the evolution of resistance and
93 overview of the mechanisms of interaction of coinfecting pathogens, ranging from immune modulation an
98 , all-oral, pan-GT HCV treatment for HIV-HCV coinfected patients across a broad range of ARV regimens
100 itoring could be reduced in monoinfected and coinfected patients by estimating the probability of mai
101 -IRIS patients and non-IRIS controls (HIV-TB-coinfected patients commencing antiretroviral therapy wh
102 ative risk of tuberculosis transmission from coinfected patients compared to HIV-negative patients wi
104 y with DAA-containing therapy, excluding HIV coinfected patients from clinical trials of DAA-containi
105 Mycobacterium tuberculosis (Mtb) and HIV in coinfected patients has profoundly impacted global morta
109 incidence of recent HDV infection in HIV/HBV-coinfected patients increased significantly from 1992-20
110 nalyzed HCV treatment outcomes among 255 HCV coinfected patients initiating DAAs between February 201
111 r (OPrD) +/- RBV in HIV/HCV genotype 1 (GT1)-coinfected patients initiating HCV therapy in clinical p
112 Our data suggest that eradication of HCV in coinfected patients is associated not only with a reduct
117 icacy and safety of OBV/PTV/r + DSV + RBV in coinfected patients on stable, DRV-containing antiretrov
118 randomized, open-label ALLY-2 study, HIV-HCV-coinfected patients received 8 or 12 weeks of once-daily
121 in CD4 T cells from HIV-1/hepatitis C virus-coinfected patients receiving highly active antiretrovir
123 Over a 2-year period, only 36.0% of HIV/HBV coinfected patients seen in HIV practices completed HCC
124 In patients with serial samples, only MRSA-coinfected patients showed time-dependent increases in a
125 , and D-dimer (P = .0444) were also found in coinfected patients than in HIV-positive/CMV-negative su
127 t that ART should be administered to HIV/HCV-coinfected patients to lower the risk of end-stage liver
130 ficiency virus (HIV)/hepatitis C virus (HCV)-coinfected patients treated with interferon (IFN) and ri
131 is study, we report on treatment outcomes of coinfected patients up to 18 months following treatment
138 man immunodeficiency virus/hepatitis C virus-coinfected patients who relapsed after receiving 12 week
139 study was conducted in HIV/HCV genotype 1/4-coinfected patients who were null responders to prior pe
141 ficiency virus (HIV)/hepatitis C virus (HCV)-coinfected patients with cirrhosis have long been consid
143 ial count, this rate was lower, but 97.6% of coinfected patients with initial counts >350 cells/micro
145 cirrhosis, HCC, or overall mortality between coinfected patients with undetectable HBV DNA and those
147 uo results in delayed access to DAAs for HIV coinfected patients, a group with more rapid progression
148 deficiency virus-hepatitis C virus (HIV-HCV)-coinfected patients, a population also concerned with el
149 mpairment in PRO scores was noted in HIV/HCV-coinfected patients, compared with HCV-monoinfected pati
175 Fibrosis progression is common among HIV/HCV coinfected patients; these data suggest that progression
178 plasma HIV-1 viral load (VL) in HIV-1/HSV-2 coinfected persons, and this was proposed to be due to a
184 ding opportunities for divergent lineages to coinfect, reassort, and generate new viral genotypes.
185 milar 5-year and 10-year GS, whereas HIV/HCV coinfected recipients had worse GS (5-year: 64.0% versus
188 virus (HIV) and HIV/hepatitis C virus (HCV) coinfected recipients in the United States is unknown.
189 lthough allograft loss was higher in HIV/HCV coinfected recipients transplanted at enrolling (HR 2.64
191 f 106 human immunodeficiency virus (HIV)/HBV-coinfected subjects maintained on lamivudine, as well as
193 increasing the chances for the virophage to coinfect the host cell with an NCLDV prey and (ii) defen
196 S. pneumoniae serotype (ST) 6A or 8 and then coinfected them with mouse-adapted H1N1 influenza A viru
199 o-platelet ratio index [APRI]) among HIV-HCV-coinfected users of modern protease inhibitor (PI)- and
200 45.9% of HCV-infected, and 33.8% of HIV/HCV-coinfected veterans had an indication for statin therapy
202 inical Case Registry to identify HIV/HCV GT1-coinfected veterans initiating 12 weeks of LDV/SOF +/- R
204 re, significant protection against unrelated coinfecting viral pathogens can be conferred by combinin
206 terial, we show reassortment between the two coinfecting viruses occurred with high likelihood direct
207 he sensitivity of virus detection, including coinfecting viruses, and expanded our ability to detect
213 berculosis (65% human immunodeficiency virus coinfected) were intensively sampled to determine rifamp
217 Sclerotinia sclerotiorum isolate 328 was coinfected with a strain of Sclerotinia sclerotiorum end
222 dy of liver fibrosis progression in patients coinfected with HCV and HIV, using the well-characterize
224 ect has been little investigated in patients coinfected with HCV and human immunodeficiency virus (HI
225 controlled study, patients with HIV who were coinfected with HCV genotype 1, 2, or 3 who received the
226 However, outcomes among HIV+ LT recipients coinfected with HCV remain concerning and motivate futur
229 munodeficiency virus (HIV)-infected patients coinfected with hepatitis B (HBV) and C (HCV) viruses ar
231 l cohort study (eight countries), 37 (6%; 32 coinfected with hepatitis C virus [HCV] and five with he
234 ents with cirrhosis, patients with cirrhosis coinfected with HIV and HCV frequently present at radiol
236 placebo-controlled trial among 3408 persons coinfected with HIV and herpes simplex virus type 2.
238 revious investigations suggest that patients coinfected with HIV and tuberculosis are less likely to
239 nd especially among children <5 years of age coinfected with HIV or malaria, or who are compromised b
240 atients were excluded if they were pregnant, coinfected with HIV, or infected with hepatitis B, C, or
242 e-group, open-label study involving patients coinfected with HIV-1 and genotype 1 or 4 HCV receiving
252 IV acquisition by hCD4/R5/cT1 mice vaginally coinfected with HSV-2 could be completely prevented in a
254 considered the ideal treatment for patients coinfected with human immunodeficiency virus (HIV) and h
255 recent HDV superinfection among individuals coinfected with human immunodeficiency virus (HIV) and H
257 er fibrosis progresses faster in individuals coinfected with human immunodeficiency virus (HIV) and h
258 There are considerable numbers of patients coinfected with human immunodeficiency virus (HIV) and v
259 was determined longitudinally among 96 women coinfected with human immunodeficiency virus (HIV), herp
260 ffective these drugs will be for individuals coinfected with human immunodeficiency virus (HIV)-HCV.
261 or hepatitis C virus (HCV) excluded patients coinfected with human immunodeficiency virus (HIV).
262 ects of THC on fibrosis progression in women coinfected with human immunodeficiency virus (HIV)/HCV e
263 rosis progression in a large cohort of women coinfected with human immunodeficiency virus (HIV)/HCV.
264 A prospective observational study of 176 men coinfected with human immunodeficiency virus and herpes
265 y and safety of this combination in patients coinfected with human immunodeficiency virus type 1 (HIV
266 ment for hepatitis C virus (HCV) in patients coinfected with human immunodeficiency virus type 1 (HIV
267 epatitis C virus (HCV) infection in patients coinfected with human immunodeficiency virus type 1 (HIV
269 tuberculosis infection, especially in women coinfected with human immunodeficiency virus; (2) evalua
270 he B cell response to IAV is altered in mice coinfected with IAV and S. pneumoniae and that this resp
272 single virions released from cells that were coinfected with M tagged with enhanced green fluorescent
273 ation capacity were compared across children coinfected with MRSA or methicillin-susceptible S. aureu
276 t adults and adolescents, including patients coinfected with other sexually transmitted infections (s
277 ctive effect in SIV-infected African monkeys coinfected with pegiviruses, possibly because SIV causes
278 fractions from Nicotiana benthamiana plants coinfected with Q-satRNA and its HV confirmed the associ
283 usly shown that 11 patients became naturally coinfected with seasonal H1N1 (A/H1N1) and pandemic H1N1
285 h the human immunodeficiency virus (HIV) are coinfected with the hepatitis C virus (HCV) due to share
286 he ongoing outbreak in Sierra Leone, 13 were coinfected with the immunomodulatory pegivirus GB virus
288 virological response (SVR) rates in the HIV coinfected with those in the HCV monoinfected treated wi
290 fector CD8(+) T cells to mice that were then coinfected with two Plasmodium berghei strains, only one
291 , controlled levels of defective viruses are coinfected with viable viruses that have been engineered
292 ts have not been very promising for patients coinfected with VL and human immunodeficiency virus.
294 red with healthy reference patients, HIV/HCV-coinfected women had decreased tibial trabecular volumet
300 nosa and S. aureus may benefit each other by coinfecting wounds and that the host-derived matrix may
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。